Yellow fever virus
According to the World Health Organisation there are 47 countries in Africa and Central & South America that are either endemic for, or have regions that are endemic for, yellow fever. A 2013 study estimated the burden of yellow fever was 84 000–170 000 severe cases and 29 000–60 000 deaths.
At The Native Antigen Company we offer a range of recombinant YFV antigens, and highly specific monoclonal antibodies to support research into the infection and assay development.
Yellow Fever virus background
Yellow fever is an acute hemorrhagic disease caused by the yellow fever virus (YFV), which is a member of the Flaviviridae family of viruses. Clinical symptoms of the disease include fever, muscle pain, nausea and vomiting. In a small percentage of patients, the liver and kidneys are affected leading to jaundice, and in some cases death. In the sylvatic cycle, the virus is transmitted to non-human primates via mosquitoes of the Haemagogus and Sabethes genera. Whereas the Aedes aegypti mosquito is responsible for the transmission of YFV to humans in urban areas. Yellow fever virus is endemic in tropical areas of Africa and Central/South America where the vector is widespread.
In the late 1930’s a safe and effective attenuated vaccine was developed against the YFV, which confers long-term immunity. Since its introduction, the vaccine has been used successfully to immunize individuals in areas where YFV is endemic.
Diagnosis of yellow fever is complicated by the fact that early symptoms of the infection can be confused with other haemorrhagic diseases including Dengue. Differential diagnosis is therefore an important consideration in areas where other flaviviruses such as Dengue and Zika co-circulate
- Norrby E (2007). Yellow fever and Max Theiler: the only Nobel Prize for a virus vaccine. J Exp Med. 204 (12):277
Yellow fever virus Antigens
The Native Antigen Company prepare recombinant Yellow Fever virus NS1 protein in a proprietary mammalian cell expression system, which generates highly pure NS1 protein in glycosylated form and predominantly in hexameric format.
Yellow fever virus Antibodies
We have used our recombinant Yellow Fever virus NS1 protein to raise a panel of specific antibodies to YFV NS1 protein, all of which are highly specific and do not cross-react with NS1 proteins from other flaviviruses, including Dengue, West Nile and Japanese Encephalitis viruses
Check out our FAQ section for answers to the most frequently asked questions about our website and company.